Drug Development

Home
>
Drug Development

Stillmeadow Incorporated: Pioneering Drug Development for a Healthier Tomorrow

Before testing a drug in people, researchers must find out whether it has the potential to cause serious harm, also called toxicity. Starting with Acute screens and advancing to Sub Chronic studies we are available to help with your (IND) Initial New Drug development program.

Drug Development Program:

The successful FDA approval of your Investigational New Drug (IND) application begins with STILLMEADOW, Inc.
Our AAALAC Accredited Lab boasts over 75,000 sq ft of lab space and a trained staff, ensuring comprehensive testing.

For the past 45 years, STILLMEADOW, Inc. has been dedicated to providing top-tier testing services, supporting drug development programs with the expertise and resources needed to achieve FDA approval.

Our Approach: At STILLMEADOW, we take a comprehensive approach to drug development, integrating the latest scientific advancements with a deep understanding of our sponsors’ needs. Our multidisciplinary team collaborates closely to identify the types of toxicology studies for potential drugs, medical procedures, and medical devices for human therapeutic use.
Rigorous Testing: Quality and safety are paramount. Our preclinical drug testing meets the highest regulatory standards and exceeds expectations of excellence.
Pipeline of Innovation: Our diverse portfolio reflects the wide variety of preclinical testing available, with rodent and non-rodent species, pharmacokinetic analysis (PK) of drug absorption, distribution, metabolism, and excretion (ADME studies), 28 to 90 day chronic toxicological studies and with dose range-finding studies.
Partnering for Success: From guidance in the creation of unique pilot studies and protocols, to evaluation of the safety and efficacy of your drug, STILLMEADOW Inc.’s experienced Study Directors and Laboratory Technicians support your Drug Development Team in meeting FDA guidelines for approval of your Investigational New Drug (IND) application.

Frequently Asked Questions

What does STILLMEADOW, Inc. offer for drug development?

At STILLMEADOW, Inc., the drug development process starts with the preclinical testing. By offering a complete range of preclinical testing and the expertise of our fully trained and experienced staff, we can assist you in designing the right protocol for your specific purpose.

How does STILLMEADOW, Inc. collaborate with grant recipients and other types of government funded sponsors?

STILLMEADOW, Inc. is cognizant that research is not conducted in a vacuum. Many times there are multiple parties working together to bring a drug to market. We can communicate timely results with all parties involved and will always strive to meet required deadlines.

How does STILLMEADOW, Inc. handle testing across different disciplines?

We will typically have one study director as an overall point of contact but who stays in close communication with all study directors involved. In this way, a specific series of required testing among multiple departments can be efficiently and expertly managed.

What are some of the preclinical testing that STILLMEADOW, Inc. offers?

STILLMEADOW, Inc. offers 28-day and 90-day chronic toxicity testing. We offer rodent and non-rodent toxicity testing, in addition to the most robust analytical chemistry profile. We offer pharmacokinetic (PK) testing for drug absorption, distribution, metabolism, and excretion (ADME tests). Our toxicologists often work with clients to design protocols for specific purposes that may lie outside the areas previously mentioned, such as non-GLP screening tests, pilot studies, and other exploratory projects.

We hope these FAQs have provided you with a better understanding of what STILLMEADOW, Inc. and our commitment to comprehensive preclinical testing can provide for you. If you have any further questions or inquiries, please don’t hesitate to reach out to us. Thank you for your interest in STILLMEADOW, Inc.